{
    "xml": "<topic id=\"PHP5390\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/pemetrexed\" basename=\"pemetrexed\" title=\"PEMETREXED\">\n<title>PEMETREXED</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1171\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/pemetrexed\">Pemetrexed</xref>\n</p>\n<data name=\"vtmid\">411089001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_699299946\" title=\"Antimetabolites\">Antimetabolites</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP67709\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/pemetrexed\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Pemetrexed inhibits thymidylate transferase and other folate-dependent enzymes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67664\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/pemetrexed\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of unresectable malignant pleural mesothelioma which has not previously been treated with chemotherapy (in combination with cisplatin)</p>\n<p outputclass=\"therapeuticIndication\">First-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (in combination with cisplatin)</p>\n<p outputclass=\"therapeuticIndication\">Second-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (monotherapy)</p>\n<p outputclass=\"therapeuticIndication\">Maintenance treatment in locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following platinum-based chemotherapy (monotherapy)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67767\" outputclass=\"cautions\" rev=\"1.9\" parent=\"/drugs/pemetrexed\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Diabetes</ph>; <ph outputclass=\"caution\">history of cardiovascular disease</ph>; <ph outputclass=\"caution\">prophylactic folic acid supplementation required (consult product literature)</ph>; <ph outputclass=\"caution\">prophylactic vitamin B<sub>12 </sub> supplementation required (consult product literature)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67651\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/pemetrexed\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Caution with concomitant nephrotoxic drugs including non-steroidal anti-inflammatory drugs (consult product literature).</p>\n<p>Appendix 1 (pemetrexed).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67530\" outputclass=\"sideEffects\" rev=\"1.10\" parent=\"/drugs/pemetrexed\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Conjunctivitis</ph>; <ph outputclass=\"sideEffect\">dehydration</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disturbances</ph>; <ph outputclass=\"sideEffect\">increased lacrimation</ph>; <ph outputclass=\"sideEffect\">neuropathy</ph>; <ph outputclass=\"sideEffect\">oedema</ph>; <ph outputclass=\"sideEffect\">skin disorders</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arrhythmias</ph>; <ph outputclass=\"sideEffect\">colitis</ph>; <ph outputclass=\"sideEffect\">interstitial pneumonitis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Acute renal failure</ph>; <ph outputclass=\"sideEffect\">hepatitis</ph>; <ph outputclass=\"sideEffect\">peripheral ischaemia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67748\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/pemetrexed\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67628\" outputclass=\"pregnancy\" parent=\"/drugs/pemetrexed\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (toxicity in <i>animal</i> studies).</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67776\" outputclass=\"breastFeeding\" parent=\"/drugs/pemetrexed\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67566\" outputclass=\"renalImpairment\" parent=\"/drugs/pemetrexed\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid if creatinine clearance less than 45&#8239;mL/minute&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67414\" outputclass=\"nationalFunding\" rev=\"1.22\" parent=\"/drugs/pemetrexed\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA124</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Pemetrexed for the treatment of non-small cell lung cancer (August 2007)</p>\r\n<p>Pemetrexed is <b>not</b> recommended for the treatment of locally advanced or metastatic non-small cell lung cancer which has previously been treated with chemotherapy.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA124\">www.nice.org.uk/TA124</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA135</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008)</p>\r\n<p>Pemetrexed is an option for the treatment of malignant pleural mesothelioma only in patients who have a WHO performance status of 0 or 1 [WHO performance status is a measure of the ability to perform ordinary tasks], who are considered to have advanced disease and for whom surgical resection is considered inappropriate.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA135\">www.nice.org.uk/TA135</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA181</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Pemetrexed for the first-line treatment of non-small cell lung cancer (September 2009)</p>\r\n<p>Pemetrexed, in combination with cisplatin, is an option for the first-line treatment of locally advanced or metastatic non-small cell lung cancer only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA181\">www.nice.org.uk/TA181</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA190</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Pemetrexed for the treatment of non-small cell lung cancer (June 2010)</p>\r\n<p>Pemetrexed is an option for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following combination therapy of a platinum compound with either gemcitabine, paclitaxel, or docetaxel.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA190\">www.nice.org.uk/TA190</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA309</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (April 2014)</p>\r\n<p>Pemetrexed is <b>not</b> recommended for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer in patients whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA309\">www.nice.org.uk/TA309</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (August 2008) that pemetrexed (<i>Alimta</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland as monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer without predominantly squamous cell histology; it is restricted for use in patients with good performance status who would otherwise be eligible for docetaxel treatment.</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (January 2010) that pemetrexed (<i>Alimta</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland in combination with cisplatin for the first-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology; it is restricted to patients in whom the histology of the tumour has been confirmed as adenocarcinoma or large cell carcinoma.</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (July 2005) that pemetrexed (<i>Alimta</i>\r\n<tm tmtype=\"reg\"/>) in combination with cisplatin is accepted for restricted use within NHS Scotland for previously untreated patients with stage III/IV unresectable malignant pleural mesothelioma.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5390-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/pemetrexed\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76041\" title=\"Powder for solution for infusion\" namespace=\"/drugs/pemetrexed/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1171\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/pemetrexed\" title=\"Pemetrexed\" count=\"1\" rel=\"link\">Pemetrexed</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76041\" namespace=\"/drugs/pemetrexed/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5390",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/pemetrexed",
    "basename": "pemetrexed",
    "title": "PEMETREXED",
    "interactants": [
        {
            "id": "bnf_int_1171",
            "label": "Pemetrexed"
        }
    ],
    "vtmid": "411089001",
    "drugClassification": [
        "Antimetabolites"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Pemetrexed inhibits thymidylate transferase and other folate-dependent enzymes.",
                "html": "<p>Pemetrexed inhibits thymidylate transferase and other folate-dependent enzymes.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of unresectable malignant pleural mesothelioma which has not previously been treated with chemotherapy (in combination with cisplatin)",
                        "html": "Treatment of unresectable malignant pleural mesothelioma which has not previously been treated with chemotherapy (in combination with cisplatin)"
                    },
                    {
                        "textContent": "First-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (in combination with cisplatin)",
                        "html": "First-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (in combination with cisplatin)"
                    },
                    {
                        "textContent": "Second-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (monotherapy)",
                        "html": "Second-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (monotherapy)"
                    },
                    {
                        "textContent": "Maintenance treatment in locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following platinum-based chemotherapy (monotherapy)",
                        "html": "Maintenance treatment in locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following platinum-based chemotherapy (monotherapy)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Diabetes",
                "html": "Diabetes"
            },
            {
                "type": "cautions",
                "textContent": "history of cardiovascular disease",
                "html": "history of cardiovascular disease"
            },
            {
                "type": "cautions",
                "textContent": "prophylactic folic acid supplementation required (consult product literature)",
                "html": "prophylactic folic acid supplementation required (consult product literature)"
            },
            {
                "type": "cautions",
                "textContent": "prophylactic vitamin B12 supplementation required (consult product literature)",
                "html": "prophylactic vitamin B<sub>12 </sub> supplementation required (consult product literature)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Caution with concomitant nephrotoxic drugs including non-steroidal anti-inflammatory drugs (consult product literature).\n\nAppendix 1 (pemetrexed).",
                "html": "<p>Caution with concomitant nephrotoxic drugs including non-steroidal anti-inflammatory drugs (consult product literature).</p><p>Appendix 1 (pemetrexed).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Conjunctivitis",
                        "html": "Conjunctivitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dehydration",
                        "html": "dehydration",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-intestinal disturbances",
                        "html": "gastro-intestinal disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "increased lacrimation",
                        "html": "increased lacrimation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "neuropathy",
                        "html": "neuropathy",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "skin disorders",
                        "html": "skin disorders",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Arrhythmias",
                        "html": "Arrhythmias",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "colitis",
                        "html": "colitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "interstitial pneumonitis",
                        "html": "interstitial pneumonitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Acute renal failure",
                        "html": "Acute renal failure",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hepatitis",
                        "html": "hepatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "peripheral ischaemia",
                        "html": "peripheral ischaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (toxicity in animal studies).\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (toxicity in <i>animal</i> studies).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid if creatinine clearance less than 45 mL/minute&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid if creatinine clearance less than 45&#8239;mL/minute&#8212;no information available.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA124",
                        "label": "www.nice.org.uk/TA124"
                    }
                ],
                "fundingIdentifier": "NICE TA124",
                "textContent": "Pemetrexed for the treatment of non-small cell lung cancer (August 2007) Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small cell lung cancer which has previously been treated with chemotherapy.\n\nwww.nice.org.uk/TA124",
                "html": "<p outputclass=\"title\">Pemetrexed for the treatment of non-small cell lung cancer (August 2007)</p> <p>Pemetrexed is <b>not</b> recommended for the treatment of locally advanced or metastatic non-small cell lung cancer which has previously been treated with chemotherapy.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA124\">www.nice.org.uk/TA124</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA135",
                        "label": "www.nice.org.uk/TA135"
                    }
                ],
                "fundingIdentifier": "NICE TA135",
                "textContent": "Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008) Pemetrexed is an option for the treatment of malignant pleural mesothelioma only in patients who have a WHO performance status of 0 or 1 [WHO performance status is a measure of the ability to perform ordinary tasks], who are considered to have advanced disease and for whom surgical resection is considered inappropriate.\n\nwww.nice.org.uk/TA135",
                "html": "<p outputclass=\"title\">Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008)</p> <p>Pemetrexed is an option for the treatment of malignant pleural mesothelioma only in patients who have a WHO performance status of 0 or 1 [WHO performance status is a measure of the ability to perform ordinary tasks], who are considered to have advanced disease and for whom surgical resection is considered inappropriate.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA135\">www.nice.org.uk/TA135</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA181",
                        "label": "www.nice.org.uk/TA181"
                    }
                ],
                "fundingIdentifier": "NICE TA181",
                "textContent": "Pemetrexed for the first-line treatment of non-small cell lung cancer (September 2009) Pemetrexed, in combination with cisplatin, is an option for the first-line treatment of locally advanced or metastatic non-small cell lung cancer only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.\n\nwww.nice.org.uk/TA181",
                "html": "<p outputclass=\"title\">Pemetrexed for the first-line treatment of non-small cell lung cancer (September 2009)</p> <p>Pemetrexed, in combination with cisplatin, is an option for the first-line treatment of locally advanced or metastatic non-small cell lung cancer only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA181\">www.nice.org.uk/TA181</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA190",
                        "label": "www.nice.org.uk/TA190"
                    }
                ],
                "fundingIdentifier": "NICE TA190",
                "textContent": "Pemetrexed for the treatment of non-small cell lung cancer (June 2010) Pemetrexed is an option for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following combination therapy of a platinum compound with either gemcitabine, paclitaxel, or docetaxel.\n\nwww.nice.org.uk/TA190",
                "html": "<p outputclass=\"title\">Pemetrexed for the treatment of non-small cell lung cancer (June 2010)</p> <p>Pemetrexed is an option for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following combination therapy of a platinum compound with either gemcitabine, paclitaxel, or docetaxel.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA190\">www.nice.org.uk/TA190</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA309",
                        "label": "www.nice.org.uk/TA309"
                    }
                ],
                "fundingIdentifier": "NICE TA309",
                "textContent": "Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (April 2014) Pemetrexed is not recommended for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer in patients whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin.\n\nwww.nice.org.uk/TA309",
                "html": "<p outputclass=\"title\">Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (April 2014)</p> <p>Pemetrexed is <b>not</b> recommended for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer in patients whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA309\">www.nice.org.uk/TA309</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76041",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1171",
                "label": "Pemetrexed",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76041",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}